Neurogen Announces Positive Results for Aplindore in Restless Legs Syndrome and Parkinson's...

Tuesday October 14, 7:00 am ET --Conference call scheduled for 8:30 a.m. today-- BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN - News ) today announced positive top-line results from two Phase 2 clinical trials in restless legs syndrome (RLS) and Parkinson’s disease with the Company’s dopamine partial agonist, aplindore. These studies were the first in which aplindore has been evaluated in RLS and Parkinson’s disease. In each study, aplindore demonstrated highly significant efficacy and was well tolerated. Neurogen believes aplindore’s dopamine partial agonist controlled release profile may be better tolerated, with fewer side effects and greater dosing flexibility, than existing drugs to treat RLS and Parkinson’s disease. Side effects of RLS drugs currently on the market or in late-stage development... [read full story]